Immune disorders are a leading cause of morbidity and long-term health challenges among children worldwide. Recent decades ...

Take a closer look at the radiopharma new wave as Nuclidium and Actithera raise big to develop their platforms.

Tumor therapy has evolved significantly over recent decades, yet tumors continue to develop resistance to conventional ...

As patients lay on beds with massive machines swirling around them during radiation therapy, one simple obstacle stands in the way of the complex technology delivering optimal cancer treatment: ...

SNMMI annual meeting featured a clinical diagnosis and therapy session and a presentation by Dr. Kambiz Rahbar discussing the clinical value of the PROSTest to detect biochemical recurrence in ...

Preliminary results of an observational clinical trial underway at Roswell Park Comprehensive Cancer Center are shedding ...

The Minneapolis-based medtech company can now market its wearable sensor, eMotus, to hospitals and cancer centers.

The review introduces the molecular subtypes of breast cancer and outlines how altered amino acid metabolism supports tumor ...

Our fair value estimate for Philips is EUR 35 per share. While the litigation settlement is an important milestone, the company continues to operate under the consent decree, preventing it from ...

With darting red and green beams above me and large mechanical eyes and grids humming and moving around me, I feel as though I’m in a 1950s sci-fi movie.

While data is promising, many questions remain about topics such as timing and doses in the treatment of hematologic malignancies.

The Korea Research Institute of Standards and Science has successfully developed a nanomaterial capable of simultaneously ...